Ensembles de batteries rechargeables spécifiques aux clients

Informations de base

• Disponible sur:
• English
• Français

Product Description:

The EarlyTect Colon Cancer Test is a groundbreaking product that has been approved by the Korea Ministry of Food and Drug Safety, following extensive clinical trials conducted at reputable medical centers such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center. This test is specifically designed for individuals between the ages of 30 to 80 and has shown remarkable results.

Through the utilization of fecal DNA analysis, the clinical trials have demonstrated that the EarlyTect Colon Cancer Test is able to accurately diagnose colorectal cancer with an impressive 90% sensitivity and specificity. By measuring the presence of methylated Syndecan-2, a biomarker closely associated with precancerous lesions of colorectal cancer, this qualitative real-time PCR test has proven to be highly effective.

It is important to note that the EarlyTect Colon Cancer Test is not intended to provide a definitive confirmation of colorectal cancer. Rather, it serves as a valuable tool for identifying the presence of colorectal cancer or precancerous lesions. Therefore, if a subject receives a positive result from this test, it is advised that they seek further medical evaluation to determine the extent and nature of the condition.

Product Standard:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals undergoing colorectal cancer screening
- Biomarker: SDC2 methylation

Please note that the price and transaction conditions for the EarlyTect Colon Cancer Test are negotiable. For more information and to request a quote, please contact us.